Nivolumab and Ipilimumab +/-UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

被引：0
|
作者：
Haakensen, V. [1 ]
Nowak, A. [2 ]
Ellingsen, E. [3 ]
Grundberg, O. [4 ]
Farooqi, S. [1 ]
Mcculloch, T. [5 ]
Cedres, S. [6 ]
Bjaanaes, M. [1 ]
Helland, A. [7 ,8 ]
机构：
[1] Oslo Univ Hosp, Div Canc Med, Oslo, Norway
[2] Univ Western Australia, Natl Ctr Asbestos Related Dis, Crawley, ACT, Australia
[3] Ultimovacs Asa, Oslo, Norway
[4] Karolinska Inst, Stockholm, Sweden
[5] Aalborg Univ Hosp, Aalborg, Denmark
[6] Vall Dhebron Inst Oncol Vhio, Med Oncol, Vall Dhebron Barcelona Hosp Campus, Barcelona, Spain
[7] Univ Oslo, Clin Med, Oslo, Norway
[8] Oslo Univ Hosp, Oslo, Norway
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Immunotherapy; Mesothelioma; clinical trial;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P24.07
引用
收藏
页码：S380 / S380
页数：1
相关论文
共 50 条
  • [1] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    Vilde Drageset Haakensen
    Anna K. Nowak
    Espen Basmo Ellingsen
    Saima Jamil Farooqi
    Maria Moksnes Bjaanæs
    Henrik Horndalsveen
    Tine Mcculloch
    Oscar Grundberg
    Susana M. Cedres
    Åslaug Helland
    Journal of Translational Medicine, 19
  • [2] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    Haakensen, Vilde Drageset
    Nowak, Anna K.
    Ellingsen, Espen Basmo
    Farooqi, Saima Jamil
    Bjaanaes, Maria Moksnes
    Horndalsveen, Henrik
    Mcculloch, Tine
    Grundberg, Oscar
    Cedres, Susana M.
    Helland, Aslaug
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [3] First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma
    Helland, A.
    Haakensen, V. D.
    Ojlert, A. K.
    Thunold, S. M. H.
    Nowak, A. K.
    Chin, W. L.
    Grundberg, O.
    Farooqi, S. J.
    Lund-Iversen, M.
    Szejniuk, W. M.
    Perez, S. M. Cedres
    Sorensen, J. B.
    Bjaanaes, M. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1337 - S1337
  • [4] Nivolumab and ipilimumab +/-UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial).
    O'Day, Steven
    Bechter, Oliver
    Lorigan, Paul
    Nyakas, Marta
    CANCER RESEARCH, 2021, 81 (13)
  • [5] UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
    Haakensen, Vilde Drageset
    Ojlert, Asa Kristina
    Thunold, Solfrid
    Farooqi, Saima
    Nowak, Anna K.
    Chin, Wee L.
    Grundberg, Oscar
    Szejniuk, Weronika Maria
    Cedres, Susana
    Sorensen, Jens Benn
    Dalen, Tonje Sofie
    Lund-Iversen, Marius
    Bjaanaes, Maria
    Helland, Aslaug
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [6] Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
    Lorigan, Paul
    Medina, Theresa
    Nyakas, Marta
    Rutten, Annemie
    Feun, Lynn G.
    Cowey, Charles Lance
    Payne, Miranda
    Hussain, Israr
    Kuzel, Timothy
    O'Day, Steven
    Sheri, Amna
    Friedlander, Philip Adam
    Kumar, Satish
    Bjorheim, Jens
    Bechter, Oliver Edgar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9519 - LBA9519
  • [7] Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study
    Disselhorst, M.
    Harms, E.
    Van Tinteren, H.
    Quispel-Janssen, J.
    Monkhorst, K.
    Burgers, S.
    Baas, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1746 - S1746
  • [8] Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/-UV1 telomerase vaccine
    Thunold, Solfrid
    Hernes, Eivor
    Farooqi, Saima
    Oejlert, asa Kristina
    Francis, Roslyn J.
    Nowak, Anna K.
    Szejniuk, Weronika Maria
    Nielsen, Soren Steen
    Cedres, Susana
    Perdigo, Marc Simo
    Sorensen, Jens Benn
    Meltzer, Carin
    Mikalsen, Lars Tore Gyland
    Helland, Aslaug
    Malinen, Eirik
    Haakensen, Vilde Drageset
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025, 52 (02) : 693 - 707
  • [9] Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
    Ye, Zhuo-miao
    Tang, Zi-Qing
    Xu, Zhe
    Zhou, Qin
    Li, Huan
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [10] 2nd line chemotherapy in malignant mesothelioma: A center's experience
    Vassos, D.
    Tsironis, G.
    Kopitopoulou, A.
    Tsagkouli, S.
    Tsimpoukis, S.
    Charpidou, A.
    Bamias, A.
    Syrigos, K.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S148 - S149
12345